In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

This week’s clinical update looks at 3 clinical trials for the treatment of sickle cell disease (SCD), relapsed or refractory blood cancers and...

This week’s clinical update looks at 3 clinical trials for CRISPR-edited CAR T therapies for the treatment of B-cell cancers or multiple myeloma.

This week’s clinical update looks at two clinical trials for beta thalassemia using CRISPR-Cas9-edited donor-derived haematopoeitic stem cells (HSCs).

This week’s update looks at DA01, the first gene-edited cell therapy for Parkinson’s disease (PD) to reach IND stage.

This week’s update looks at a Phase 1 clinical trial for a new meganuclease-edited CAR T-cell therapy for Non-Hodgkin lymphoma (NHL).

A new generation of therapies based on CRISPR-Cas and other gene-editing technologies brings hope to the millions of people living with a rare genetic...

This week’s gene-editing clinical trial update looks at a universal dual specificity CD19 and CD20/CD22 CAR-T cell immunotherapy that is being...